Literature DB >> 17088946

Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.

Andrea Molnár1, Attila Tóth, Zsolt Bagi, Zoltán Papp, István Edes, Miklós Vaszily, Zoltán Galajda, Julius Gy Papp, András Varró, Viktória Szüts, Zsombor Lacza, Domokos Gerö, Csaba Szabó.   

Abstract

Poly(ADP-ribose) polymerase (PARP) activation has been implicated in the pathogenesis of acute and chronic myocardial dysfunction and heart failure. The goal of the present study was to investigate PARP activation in human heart failure, and to correlate PARP activation with various indices of apoptosis and oxidative and nitrosative stress in healthy (donor) and failing (NYHA class III-IV) human heart tissue samples. Higher levels of oxidized protein end-products were found in failing hearts compared with donor heart samples. On the other hand, no differences in tyrosine nitration (a marker of peroxynitrite generation) were detected. Activation of PARP was demonstrated in the failing hearts by an increased abundance of poly-ADP ribosylated proteins. Immunohistochemical analysis revealed that PARP activation was localized to the nucleus of the cardiomyocytes from the failing hearts. The expression of full-length PARP-1 was not significantly different in donor and failing hearts. The expression of caspase-9, in contrast, was significantly higher in the failing than in the donor hearts. Immunohistochemical analysis was used to detect the activation of mitochondrial apoptotic pathways. We found no significant translocation of apoptosis-inducing factor (AIF) into the nucleus. Overall, the current data provide evidence of oxidative stress and PARP activation in human heart failure. Interventional studies with antioxidants or PARP inhibitors are required to define the specific roles of these factors in the pathogenesis of human heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088946      PMCID: PMC1626594          DOI: 10.2119/2006-00043.Molnar

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  44 in total

1.  Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst.

Authors:  Csaba Szabó; Jon G Mabley; Suzanne M Moeller; Roman Shimanovich; Pál Pacher; László Virag; Francisco G Soriano; John H Van Duzer; William Williams; Andrew L Salzman; John T Groves
Journal:  Mol Med       Date:  2002-10       Impact factor: 6.354

2.  Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity.

Authors:  Csaba Szabó; Anne Zanchi; Katalin Komjáti; Pál Pacher; Andrzej S Krolewski; William C Quist; Frank W LoGerfo; Edward S Horton; Aristidis Veves
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

Review 3.  Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure.

Authors:  Dan Sorescu; Kathy K Griendling
Journal:  Congest Heart Fail       Date:  2002 May-Jun

4.  Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction.

Authors:  Pál Pacher; Lucas Liaudet; Péter Bai; Jon G Mabley; Pawel M Kaminski; László Virág; Amitabha Deb; Eva Szabó; Zoltán Ungvári; Michael S Wolin; John T Groves; Csaba Szabó
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

5.  Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure.

Authors:  Masahiko Koda; Genzou Takemura; Motoo Kanoh; Kenji Hayakawa; Yukinori Kawase; Rumi Maruyama; Yiwen Li; Shinya Minatoguchi; Takako Fujiwara; Hisayoshi Fujiwara
Journal:  J Pathol       Date:  2003-02       Impact factor: 7.996

6.  Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.

Authors:  Pál Pacher; Lucas Liaudet; Jon g Mabley; Katalin Komjáti; Csaba Szabó
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

Review 7.  The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.

Authors:  László Virág; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

8.  Carvedilol decreases elevated oxidative stress in human failing myocardium.

Authors:  Kazufumi Nakamura; Kengo Kusano; Yoichi Nakamura; Mikio Kakishita; Keiko Ohta; Satoshi Nagase; Mika Yamamoto; Katsumasa Miyaji; Hironori Saito; Hiroshi Morita; Tetsuro Emori; Hiromi Matsubara; Shinya Toyokuni; Tohru Ohe
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

9.  Deoxyribonucleic acid damage/repair proteins are elevated in the failing human myocardium due to idiopathic dilated cardiomyopathy.

Authors:  Jozef Bartunek; Marc Vanderheyden; Michiel W N Knaapen; Wouter Tack; Mark M Kockx; Marc Goethals
Journal:  J Am Coll Cardiol       Date:  2002-09-18       Impact factor: 24.094

10.  Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure.

Authors:  Matthew J Hunt; Giorgio M Aru; Melvin R Hayden; Charles K Moore; Brian D Hoit; Suresh C Tyagi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-08       Impact factor: 5.464

View more
  22 in total

Review 1.  Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.

Authors:  Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

2.  Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice.

Authors:  Kondapalli Mrudula Spurthi; Mohsen Sarikhani; Sneha Mishra; Perumal Arumugam Desingu; Shikha Yadav; Swathi Rao; Sangeeta Maity; Ankit Kumar Tamta; Shweta Kumar; Shamik Majumdar; Aditi Jain; Aishwarya Raghuraman; Danish Khan; Ishwar Singh; Rosa J Samuel; Subbaraya G Ramachandra; Dipankar Nandi; Nagalingam R Sundaresan
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

Review 3.  Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases.

Authors:  Xueqing Ba; Nisha Jain Garg
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

4.  Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA.

Authors:  Soochan Bae; Parco M Siu; Sangita Choudhury; Qingen Ke; Jun H Choi; Young Y Koh; Peter M Kang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

6.  Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.

Authors:  Domokos Gero; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2015-10-14       Impact factor: 8.739

Review 7.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

8.  Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats.

Authors:  Sangita Choudhury; Soochan Bae; Sheetal R Kumar; Qingen Ke; Bhargavi Yalamarti; Jun H Choi; Lorrie A Kirshenbaum; Peter M Kang
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

Review 9.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

10.  Distinct cardiodynamic and molecular characteristics during early and late stages of sepsis-induced myocardial dysfunction.

Authors:  Mani Chopra; Avadhesh C Sharma
Journal:  Life Sci       Date:  2007-06-13       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.